trending Market Intelligence /marketintelligence/en/news-insights/trending/tN42SsFNztMsQgEd3AiGZg2 content esgSubNav
In This List

European Commission extends market authorization of seizure drug

Blog

Insight Weekly: Sustainable bonds face hurdles; bad loans among landlords; AI investments up

Blog

Insight Weekly: Bank oversight steps up; auto insurers’ dismal year; VC investment slumps

Blog

Insight Weekly: Renewables lead capacity additions; bank mergers of equals up; nickel IPOs surge

Blog

Insight Weekly: Utilities face headwinds; S&P 500 dividend hikes likely; dollar poised for rally


European Commission extends market authorization of seizure drug

The European Commission extended the marketed authorization of Zebinix to treat partial-onset seizures in children above the age of six.

The drug is already authorized for use in adults over the age of 18. It is marketed in Europe and Russia by Bial and by Bial's licensee, Eisai Europe Ltd.

Eisai Europe is an Eisai Co. Ltd. subsidiary.